miR-96与miR-103在肝癌组织中的表达及其与预后的关系

目的 探讨miR-96与miR-103在肝癌组织中的表达及其与预后的关系。方法 选取122例肝细胞癌患者作为本研究对象。聚合酶链式反应检测miR-96和miR-103表达水平，采用单因素和多因素Cox回归模型，探讨肝癌患者中位生存时间的危险因素并建立预测模型。结果 肝癌组织中miR-96和miR-103相对表达水平均显著高于癌旁正常组织；肝癌组织中miR-96和miR-103的表达与肿瘤直径、淋巴结转移、临床分期及分化程度均有关（均P<0.05），而与性别、年龄及合并肝硬化等无关（P>0.05）；所有患者随访60月，中位生存时间为37.8月。单因素分析结果显示：肝细胞癌患者中位生存时间与肿瘤直径、淋巴结转移、TNM分期、病理分化程度、miR-96和miR-103表达水平差异均有统计学意义（均P<0.05）。多因素分析结果显示：TNM分期为Ⅲ~Ⅳ、低分化、淋巴结转移、miR-96和miR-103高表达是肝癌患者中位生存时间独立危险因素。结论 肝癌组织中miR-96和miR-103的高表达是患者预后差的独立影响因素，可作为原发性肝癌患者预后评估指标。

Expressions of miR-96 and miR-103 in Hepatocellular Carcinoma and Their Correlation with Prognosis

Objective To explore the expressions of miR-96 and miR-103 in hepatocellular carcinoma tissues and their relation with prognosis. Methods We selected 122 patients with hepatocellular carcinoma as the observation subjects. The expression levels of miR-96 and miR-103 were detected, and univariate and multivariate Cox regression models were used to analyze the risk factors of median survival time of hepatocellular carcinoma patients and to establish a predictive model. Results The relative expression levels of miR-96 and miR-103 in hepatocellular carcinoma tissues were significantly higher than those in paracancerous tissues; the expression of miR-96 and miR-103 in HCC were correlated with tumor diameter, lymph node metastasis, clinical stage and degree of differentiation(all P<0.05). All cases were followed up for 60 months, and the median survival time was 37.8 months. The expression of miR-96 and miR-103 in HCC were correlated with tumor diameter, lymph node metastasis, clinical stage and differentiation, but not with sex, age or liver cirrhosis. Multivariate analysis showed that TNM stage Ⅲ-Ⅳ, poor differentiation, lymph node metastasis, high expression of miR-96 and miR-103 were independent risk factors for median survival time of patients with primary hepatic carcinoma. Conclusion The high expression of miR-96 and miR-103 in liver cancer tissues are the independent influence factors of poor prognosis in primary hepatic carcinoma patients and could be used as the indexes of prognostic evaluation.